ft-003
Gene therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05611424)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Molecular identity unknownINHIBITOR
Molecular identity unknown inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06492876 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2023 | Frontera Therapeutics, Tianjin Medical University |
| NCT06492863 | Phase 1/Phase 2 (Phase 2) | Aug 15, 2023 | Chinese Academy of Medical Sciences, Frontera Therapeutics, Peking University, Soochow University, Tianjin Medical University |
| NCT05916391 | Phase 1 | May 19, 2023 | Chinese Academy of Medical Sciences, Frontera Therapeutics, Tianjin Medical University, Zhengzhou University |
| NCT05611424 | Phase 1 | Nov 30, 2022 | Chinese Academy of Medical Sciences, Frontera Therapeutics, Soochow University, Tianjin Medical University, Zhengzhou University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Frontera Therapeutics | For profit | 4 | 4 | 2 | 2022 |
| Tianjin Medical University | Academic/Hospital | 4 | 0 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 2 | 2022 |
| Soochow University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Zhengzhou University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1